A first-in-class non-peptide drug conjugate entered Phase 1/2 last week, and it points at a target that peptide drugs have owned for two decades. Crinetics Pharmaceuticals' CRN09682, reported by BioWorld and reflected in the April 26 peptide-news-digest ↗, couples a small-molecule somatostatin receptor 2 (SST2) agonist to monomethyl auristatin E (MMAE), the same potent cytotoxic payload used in marketed antibody-drug conjugates, via a cleavable linker. The trial is BRAVESST2, in patients with metastatic neuroendocrine tumors and other SST2-expressing solid tumors. The competitive framing is direct. CRN09682 challenges Novartis' Lutathera and Perspective Therapeutics' alpha-PRRT, both of which are peptide-radioconjugate drugs against the same receptor.
Why SST2 is the open territory
Somatostatin receptor 2 is a well-validated target for neuroendocrine tumors. Roughly 70 to 90 percent of NETs overexpress SST2, which is what makes the receptor a useful homing beacon. The two existing therapeutic classes against this target both use peptide ligands. Octreotide and lanreotide are unconjugated peptide analogs of natural somatostatin, used as long-acting suppressive treatment for hormone-secreting NETs. Lutathera (¹⁷⁷Lu-DOTATATE) is a peptide-radioconjugate: an octreotate (octreotide-derived) peptide chemically tethered to a chelator that holds a beta-emitting lutetium-177 isotope, which is delivered into the tumor cell after receptor internalization and irradiates the cell from inside. Perspective Therapeutics' alpha-PRRT approach replaces the beta with an alpha emitter (actinium-225 or lead-212) to deposit more energy per disintegration.
What all three classes share is a peptide for receptor selectivity, plus, in the radioconjugate case, a metallic isotope for cytotoxicity. The model has worked. Lutathera is now established care for advanced midgut NETs. The supply chain, however, is fragile. Isotope production runs through a small number of reactors. Patients are dosed in nuclear-medicine windows of hours. Cold-chain logistics around radioactive material are non-trivial.
What CRN09682 does differently
Crinetics swaps both halves. The SST2 binder is a small molecule, not a peptide. The cytotoxic payload is MMAE, an auristatin-class tubulin inhibitor, not a metal isotope. The linker is cleavable, which means the payload is released inside the tumor cell after receptor internalization rather than being tethered to a chelator. The result is a drug that resembles a small-molecule version of an antibody-drug conjugate, without the antibody and without the radioactive supply chain. Manufacturing is conventional small-molecule chemistry. Distribution is normal cold-chain.
That is the trade Crinetics is making. Peptide ligands at SST2 are highly selective because the natural somatostatin sequence has been refined by evolution for receptor binding, and matching that selectivity with a small molecule is non-trivial. In exchange, manufacturing simplifies, isotope dependence disappears, and dosing logistics become standard infusion.
How this echoes Foundayo
Earlier this week we covered Lilly's Foundayo ↗, the first non-peptide GLP-1 receptor agonist. The shape of the Crinetics story is the same one. A target previously held by peptide drugs gets a small-molecule challenger that trades binding selectivity for manufacturing and logistic simplicity. In GLP-1 the trade is small-molecule binding the allosteric site of the receptor while peptides bind the natural ligand pocket. In SST2 the trade is small-molecule binding the receptor and routing a chemical payload, while peptides bind the same receptor and route a radioactive isotope.
The two trades sit at different levels (one is the receptor binding mode, one is the warhead chemistry), but the strategic move is identical: small-molecule chemistry takes a piece of receptor real estate that peptide chemistry has held for decades.
Platform context
PeptideModel's anticancer corpus ↗ hosts 196 candidate peptides, including macrocyclic and bicyclic constraint-engineered scaffolds. Lutathera-class peptides (octreotate-based, derived from somatostatin) sit in the same molecular-weight band as the bicyclic peptide-drug conjugates we covered earlier this week ↗, and the design questions overlap: receptor selectivity, internalization rate, payload release kinetics, off-target binding. CRN09682's value as a comparator point is that it lets the field benchmark what the small-molecule alternative actually delivers on each of those dimensions.
Whether the small-molecule binder matches octreotate's selectivity is the technical question the trial will answer first. Phase 1/2 readouts on tumor uptake, MMAE delivery efficiency, and SSTR1/3/4/5 cross-reactivity will tell the field whether the trade is worth the supply-chain savings. If it is, the radioligand pipeline keeps a niche but loses ground. If selectivity loss costs more than manufacturing simplicity buys, the peptide-radioconjugate model retains the territory.
What to watch
Three things. First, the BRAVESST2 dose-finding readout in NETs: tumor uptake at the maximum tolerated dose and the off-target side-effect profile. Second, whether Crinetics or follower programs report SSTR1/3/4/5 cross-reactivity data; the existing peptide drugs are functionally selective for SST2, and a small molecule that significantly hits SST5 or SST3 would carry endocrine and gastrointestinal side effects the peptides do not. Third, whether peptide-radioligand companies (Novartis with Lutathera, Perspective with alpha-PRRT, AlphaGen with the AG1002 program covered at AACR) respond by shipping longer-payload-half-life radioligands or by pivoting toward conjugate chemistry themselves.